Pathogenetic therapy in patients with COVID-19
https://doi.org/10.22625/2072-6732-2022-14-3-30-36
Abstract
The new coronavirus infection (COVID-19) has become a truly global challenge for all of humanity, and, above all, for the healthcare system. Among its most important aspects that require careful analysis are the clinical and laboratory features of the course of the disease, which make it possible to determine approaches to pathogenetic therapy in severe forms of the disease.
Materials and methods. A retrospective analysis of the medical records of patients with severe COVID-19 who were hospitalized in St. Petersburg State Budgetary Infectious Diseases Clinical Hospital named after S.P. Botkin” in 20202022. Clinical and laboratory characteristics were assessed, including levels of C-reactive protein, interleukin-6, and fever dynamics. The criteria for prescribing drugs for pathogenetic therapy in patients with COVID-19 and their effectiveness were determined.
Results. In the treatment of patients with COVID-19, it is necessary to carefully evaluate the clinical picture of the course of the disease, which is ahead of changes in laboratory parameters. The introduction of humanized antibody preparations leads to a regression of general infectious symptoms, subjective and objective manifestations of respiratory failure and, as a result, to a reduction in the length of stay of patients in the hospital. It is extremely important to timely preventive administration of drugs during the period of increasing “cytokine storm”. The optimal time for prescribing drugs is 1–3 days from the moment of receipt, until the patient is transferred to a ventilator.
About the Authors
V. A. Kapatsina
Clinical Infectious Hospital named after S.P. Botkin
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
M. A. Vashukova
Clinical Infectious Hospital named after S.P. Botkin; National Medical Research Centre named after V.A. Almazov
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
D. A. Gusev
Clinical Infectious Hospital named after S.P. Botkin; National Medical Research Centre named after V.A. Almazov
Russian Federation
Competing Interests:
Russian Federation
Saint-Petersburg
Competing Interests:
none
References
1. Barton L.M. COVID-19 Autopsies, Oklahoma, USA / L.M. Barton, E.J. Duval, E. Stroberg, S. Ghosh, S. Mukhopadhyay // Am J Clin Pathol. – 2020; XX:1-9 https://doi.org/10.1093/AJCP/AQAA062
2. Kang S. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. / S. Kang, T. Kishimoto Exp Mol Med. 2021;53(7):1116-1123. doi:10.1038/s12276021-00649-0
3. Herold T. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv (2020). https://doi.org/10.1101/2020.04.01.2004738
4. Shoenfeld Y. Corona (COVID-19) time musings: our invovement in COVID-19 pathogenesis, diagnosis, treatment ande vaccine planning // Autoimmunity reviews article in press https://doi.org/10.1016/j.autrev.2020.102538
5. Baig A.M. Evidence of COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms / A.M. Baig, A. Khalleed, U. Ali, H. Syeda // ACS Chem. neurosci. – 2020;11, 995-998
6. Gusev D.A., Vashukova M.A., Feduniak I.P., Musatov V.B., Kapatsyna V.A. Experience in the use of a recombinant humanized monoclonal antibody to the human interleukin-6 receptor in patients with COVID-19 . Journal of Infectology. 2020; 12(3): 28-32. https://doi.org/10.22625/2072-6732-2020-12-3
7. Lui T. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019 / T. Lui, J. Zhang, Y. Yang, et al. //medRxiv. – 2020. doi: https://doi.org/10.1101/2020.03.01.20029769
8. Wu C. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china / C. Wu, X. Chen, Y. Cai, et al. // JAMA. Intern Med. – 2020.
9. Ruan Q. Clinical predictors of mortality due to COVID 19 based on an analysis of data of 150 patients from Wuhan, china // Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song // Intensive Care Med. – 2020
10. Xu Z. Pathological findings of COVID-19 associated with acute respiratory distress syndrome / Z. Xu, L. Shi, Y. Wang, et al // Lancet Respir Med.- 2020.
11. “Interim guidelines” Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19). Version 15 (22.02.2022)” (approved by the Russian Ministry of Health) https://minzdrav.gov.ru/news/2022/02/22/18436-minzdravrossii-utverdil-novuyu-versiyu-vremennyh-metodicheskihrekomendatsiy-po-lecheniyu-covid-19
12. Zinserling V.A., Vashukova M.A., Vasilyeva M.V., Isakov A.N., Lugovskaya N.A., Narkevich T.A., Sukhanova Yu.V., Semenova N.Yu., Gusev D.A. Issues of pathomorphogenesis of a new coronovirus infection (COVID-19). Journal of Infectology. 2020; №2: 5-11 https://doi.org/10.22625/2072-6732-2020-12-2
13. Rose-John S. Interlieukin-6 signaling in health and disease. 2020 Aug 20;9:F1000 Faculty Rev-1013
14. Kaur S, Bansal Y, Kumar R, Bansal G. Bioorg A panoramic review of IL-6 Structure, pathophysiological roles and inhibitors, Med Chem. 2020 Mar 1;28(5):115327.
15. Bobkova S.S., Zhukov A.A., Protsenko D.N., Samoilenko V.V., Tyurin I.N.. Comparative efficacy and safety of the use of anti-IL-6 monoclonal antibodies in patients with severe novel coronavirus infection COVID-19. Retrospective cohort study. Herald of Intensive Care. 2021;1:69–76. DOI: 10.21320/1818474X-2021-1-69-76
16. Antonov V.N., Ignatova G.L., Pribytkova O.V. Experience with olokizumab in patients with COVID-19. Therapeutic archive. 2020; 92(12)
17. Association Between Administration of IL-6Antagonists and Mortality Among Haients Hospitalized for COVID-19 a Meta-analysis. 2021 Aug 10;326(6):499-518. doi:10.1001/jama.2021.11330
18. Lomakin N.V. et al. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized doubleblind placebo-controlled phase III CORONA clinical study. Inflamm. Res. (2021). https://doi.org/10.1007/s00011-02101507-51
19. Xie Z. Analysis of clinical characteristics of severe and critically ill influenza A (H1N1)/ Z. Xie, Y. Lin, Y. Chen // J. Biomed. Sc-2019;26:84
Review
For citations:
Kapatsina V.A., Vashukova M.A., Gusev D.A. Pathogenetic therapy in patients with COVID-19. Journal Infectology. 2022;14(3):30-36. (In Russ.) https://doi.org/10.22625/2072-6732-2022-14-3-30-36
Views:
539
.png)
.png)
Email this article 